Responses
Review
Trigeminal neuralgia: a practical guide
Compose a Response to This Article
Other responses
Jump to comment:
- Published on: 2 December 2021
- Published on: 2 December 2021Phenytoin in trigeminal neualgia
Your artclce mentions phenytoin as a treatment that has been tried in open label studies. When I began as a neurologist I'd not heard of its use but was put on to it by a senior colleague. I do use carbamazepine as first line but have found phenytoin far superior to other second line agents. I draw the interested reader to the excellent article by Hellelink and Schatman (J Pain Res. 2017; 10: 1663-6 doi: 10.2147/JPR.S141896) which puts a case for phenytoin being considered first line.
Conflict of Interest:
None declared.
Other content recommended for you
- Trigeminal neuralgia
- Medical treatment of SUNCT and SUNA: a prospective open-label study including single-arm meta-analysis
- Microvascular decompression of the trigeminal nerve in the treatment of SUNCT and SUNA
- Neurovascular relationship at the trigeminal root entry zone in persistent idiopathic facial pain: findings from MRI 3D visualisation
- Short-lasting unilateral neuralgiform headache attacks (SUNCT/SUNA): a narrative review of interventional therapies
- Neurovascular compression of the trigeminal and glossopharyngeal nerve: three case reports
- The PATCH trial: efficacy and safety of 5% lidocaine-medicated plaster for the treatment of patients with trigeminal neuralgia: a study protocol for a multicentric, double-blind, enriched enrolment randomised withdrawal, vehicle-controlled study
- Trigeminal neuralgia: the diagnosis and management of this excruciating and poorly understood facial pain
- Trigeminal neuralgia and its management
- Glossopharyngeal neuralgia associated with cardiac syncope